Home » Stocks » MRSN

Mersana Therapeutics, Inc. (MRSN)

Stock Price: $14.35 USD -0.16 (-1.10%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 966.21M
Revenue (ttm) 829,000
Net Income (ttm) -105.81M
Shares Out 68.99M
EPS (ttm) -1.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $14.35
Previous Close $14.51
Change ($) -0.16
Change (%) -1.10%
Day's Open 14.75
Day's Range 13.81 - 15.08
Day's Volume 711,555
52-Week Range 9.00 - 29.09

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -28.21% and -95.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the st...

3 days ago - Zacks Investment Research

- Initiated UPLIFT single-arm registration strategy for evaluation of UpRi in platinum-resistant ovarian cancer - Ended first quarter of 2021 with $228 million in cash

3 days ago - GlobeNewsWire

CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...

1 week ago - GlobeNewsWire

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...

2 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

1 month ago - GlobeNewsWire

Mersana Therapeutics Inc (NASDAQ: MRSN) has initiated patient dosing in the UPLIFT study evaluating upifitamab rilsodotin in patients with ovarian cancer. The single-arm registration strategy will evalu...

1 month ago - Benzinga

Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...

1 month ago - GlobeNewsWire

Mersana Therapeutics (MRSN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

2 months ago - GlobeNewsWire

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -27.27% and -97.65%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the...

2 months ago - Zacks Investment Research

- UPLIFT, a single-arm registration strategy evaluating upifitamab rilsodotin (UpRi) in platinum-resistant ovarian cancer, on track to begin in Q1 2021

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

3 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: CAG, ALDX, DMTK, FATE, GBIO, ORI, REVG ...
3 months ago - Benzinga

Mersana Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates ("ADCs") for cancer patients. Mersana has developed an early-stage pipeline of 8 therapeutic progra...

4 months ago - Seeking Alpha

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

4 months ago - GlobeNewsWire

The company reported disappointing clinical results.

4 months ago - The Motley Fool

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

4 months ago - GlobeNewsWire

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

Other stocks mentioned: FATE, MRNA, NTLA, RARE
4 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

4 months ago - GlobeNewsWire

Biotech investors had more than just vaccines to think about this year.

Other stocks mentioned: CRDF, FPRX, SURF, TRIL
5 months ago - The Motley Fool

CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

6 months ago - GlobeNewsWire

Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

- Webcast to be held on Monday, November 16, 2020, at 8:00 a.m. ET - - Webcast to be held on Monday, November 16, 2020, at 8:00 a.m. ET -

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

6 months ago - GlobeNewsWire

- Maintained 34% objective response rate and 79% disease control rate, including two complete responses 

7 months ago - GlobeNewsWire

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: GMAB, INVA, NVAX, REGN, TECH, VNDA, XBIT
7 months ago - Investopedia

Mersana Therapeutics: Poised To Capitalize As Billions Pour Into ADCs

7 months ago - Seeking Alpha

- Company to Host Conference Call and Webcast Featuring Study Investigator, Erika Hamilton, MD on September 17, 2020 at 8:00 a.m. ET -

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

8 months ago - GlobeNewsWire

Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

 - Presented positive interim expansion cohort data from XMT-1536 Phase 1 study at ASCO demonstrating a 35% objective response rate, including 10% complete response rate and 80% disease control rate in ...

9 months ago - GlobeNewsWire

Mersana Therapeutics (NASDAQ: MRSN) releases its next round of earnings this Friday, August 07.

9 months ago - Benzinga

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...

9 months ago - GlobeNewsWire

Here we pick five Nasdaq-listed momentum stocks that are well-poised to grow on solid prospects in the remainder of 2020.

Other stocks mentioned: BZUN, EVBG, OKTA, ZM
10 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Mersana Therapeutics.

10 months ago - Zacks Investment Research

CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...

10 months ago - GlobeNewsWire

These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.

Other stocks mentioned: AGIO, JNCE, STRO
11 months ago - The Motley Fool

Mersana Therapeutics (MRSN) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

11 months ago - Zacks Investment Research

Find Strong Buy Stocks for the Coronavirus Market Rally with this Screener

Other stocks mentioned: BGS, CODX
11 months ago - Zacks Investment Research

About MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also dev... [Read more...]

Industry
Biotechnology
IPO Date
Jun 28, 2017
CEO
Nicholas Bacopoulos
Employees
110
Stock Exchange
NASDAQ
Ticker Symbol
MRSN
Full Company Profile

Financial Performance

In 2020, MRSN's revenue was $828,000, a decrease of -98.03% compared to the previous year's $42.12 million. Losses were -$88.05 million, 212.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for MRSN stock is "Strong Buy." The 12-month stock price forecast is 28.75, which is an increase of 100.35% from the latest price.

Price Target
$28.75
(100.35% upside)
Analyst Consensus: Strong Buy